Similarly, Sonelokimab, a trivalent IL-17A/F nanobody with extended half-life by albumin binding, is under phase 3 evaluation with promising efficacy and safety [NCT06411899
Why Post-Approval Data Is the Most Commercially Valuable and Most Legally Vulnerable New Matter Post-approval discoveries new dosing regimens validated in Phase IV trials, new patient sub-populations identified through real-world evidence, device improvements incorporated into combination product submissions generate some of the highest-value secondary patents in pharmaceutical portfolios
Compounded glutathione injections are prescribed by independent licensed providers when appropriate for eligible patients
Managing Chronic Inflammation Low-grade chronic inflammation is common in PCOS and contributes to metabolic and cardiovascular risk
Providers personalize these suggestions
The FDA-approved escalation protocol starts at 2.5 mg weekly, then increases by 2.5 mg increments every four weeks until reaching a therapeutic dose between 5 mg and 15 mg per week
